Claims
- 1. A polypeptide having the ability to bind CEA comprising the amino acid sequence:
- 2. A polypeptide having the ability to bind CEA comprising the amino acid sequence:
- 3. A polypeptide having the ability to bind CEA comprising the amino acid sequence:
- 4. The polypeptide according to claim 3, wherein:
- 5. The polypeptide according to claim 3, comprising the amino acid sequence:
- 6. The polypeptide according to claim 5, having the amino acid sequence:
- 7. The polypeptide according to claim 5, comprising an amino acid sequence selected from the group consisting of:
- 8. A polypeptide having the ability to bind CEA comprising the amino acid sequence:
- 9. The polypeptide of claim 1, wherein:
- 10. The polypeptide of claim 2, wherein:
- 11. The polypeptide according to claim 2, comprising an amino acid sequence as depicted in Tables 5, 6, 8, and 9 (SEQ ID NOs: 37-109 and 113-151).
- 12. The polypeptide according to claim 1, 2, 3, 5, 8, 9, or 10, wherein said polypeptide binds to CEA but does not bind to NCA.
- 13. The polypeptide according to claim 1, 2, 3, 5, 8, 9, or 10, wherein said polypeptide has a Kd for CEA which less than 7 μM.
- 14. A method of detecting CEA in a subject comprising the steps of:
a) detectably labeling a polypeptide according to any one of claims 1-11; b) administering to said subject the labeled polypeptide; and, thereafter, c) detecting the labeled polypeptide in the subject.
- 15. The method according to claim 14, wherein said polypeptide is labeled with a radioactive compound.
- 16. The method according to claim 15, wherein said radioactive compound includes indium.
- 17. The method according to claim 15, wherein said radioactive compound includes technetium.
- 18. The method according to claim 14, wherein said detecting step is indicative of colon cancer, breast cancer, lung cancer, cervical cancer, ovarian cancer, stomach cancer, bladder cancer, pancreatic cancer or esophageal cancer.
- 19. A method of treating a CEA associated disease comprising the step of:
administering to a subject in need of treatment for such a disease a composition comprising a polypeptide according to any one of claims 1-11 conjugated with a therapeutic agent effective for treating said disease.
- 20. The method according to claim 19, wherein said CEA associated disease is colon cancer, breast cancer, lung cancer, cervical cancer, ovarian cancer, stomach cancer, bladder cancer, pancreatic cancer or esophageal cancer.
- 21. The method according to claim 19, wherein said therapeutic agent is a radioactive agent.
- 22. The method according to claim 19, wherein said therapeutic agent is a chemotherapeutic agent.
- 23. The method according to claim 19, wherein said therapeutic agent is a toxin or enzyme.
- 24. A recombinant bacteriophage expressing exogenous DNA encoding a CEA binding polypeptide having an amino acid sequence comprising:
- 25. A recombinant bacteriophage expressing exogenous DNA encoding a CEA binding polypeptide having an amino acid sequence comprising:
- 26. A recombinant bacteriophage expressing exogenous DNA encoding a CEA binding polypeptide having an amino acid sequence comprising:
- 27. A recombinant bacteriophage expressing exogenous DNA encoding a CEA binding polypeptide having an amino acid sequence comprising:
- 28. A recombinant bacteriophage expressing exogenous DNA encoding a CEA binding polypeptide having an amino acid sequence comprising:
- 29. The recombinant bacteriophage according to claim 26, expressing exogenous DNA encoding an amino acid sequence selected from the group consisting of:
- 30. The recombinant bacteriophage according to claim 25, expressing exogenous DNA encoding an amino acid sequence selected from the group of sequences depicted in Tables 5, 6, 8, and 9 (SEQ ID NOs: 37-109 and 113-151).
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. application Ser. No. 09/541,345, filed Apr. 3, 2000.
FEDERAL FUNDING
[0002] The present invention was partly supported by STTR grant no. 1R41CA79230-01. As a result, the U.S. government may retain certain rights in the invention.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09541345 |
Apr 2000 |
US |
Child |
09825517 |
Apr 2001 |
US |